Wegovy HD 7.2 mg vs 2.4 mg: Who Benefits From the Higher Dose?

Wegovy HD 7.2 mg adds about 3 percentage points of weight loss to the 2.4 mg dose on average: -18.7% vs -15.6% at 72 weeks in adults with obesity and no diabetes (difference -3.1%, 95% CI -4.7 to -1.6)^[1]. The label reserves it for adults who have tolerated 2.4 mg for at least 4 weeks and for whom more weight reduction is clinically indicated^[3]. The largest price of that gain is an abnormal skin sensation called dysesthesia, reported by 22.9% on 7.2 mg vs 6.0% on 2.4 mg^[1]. The trials reviewed here offer no test for which individual will gain enough to justify it.

Who the label allows to step up

For patients who tolerate the 2.4 mg dosage for at least 4 weeks and additional weight reduction is clinically indicated, the dosage may be increased to a maximum dosage of 7.2 mg subcutaneously once weekly.

— Wegovy prescribing information, section 2.2, revised 06/2026

That wording sets two conditions: tolerance comes first, then a clinical reason to go further. Reaching 2.4 mg alone does not meet it^[3]. On the label’s schedule, 2.4 mg begins at week 17, so the earliest step up falls about 20 weeks after starting^[3]. The option sits only under weight reduction in adults. The label’s cardiovascular maintenance language stops at 2.4 mg, and it states that the safety of 7.2 mg has “not been established in pediatric patients or patients with MASH”^[3]. Going the other way is also on-label: staying on a lower Wegovy dose is a separate question with its own evidence.

Where the extra dose pays off

The average understates what happens at the top of the range and overstates what happens at the bottom. Most people on either dose in the obesity trial (87% and 89%) lost at least 5%. The gap widens with each higher threshold, reaching about 13 more people per 100 at the 20% mark^[3].

The label flags several 2.4 mg figures, including all of those in the diabetes columns, as informational because they were left out of the trials’ hierarchical testing^[3]. The obesity comparison of mean weight change was formally tested: -3.3 points on the label’s analysis (95% CI -4.9 to -1.6), a tenth or two from the journal’s figure^[1][3]. On the 113.0 kg mean starting weight in STEP UP, 3.1 points works out to roughly 3.5 kg, or about 8 lb^[1].

The drug itself shows a flattening curve. Average steady-state concentration rises from about 75 nmol/L at 2.4 mg to about 230 nmol/L at 7.2 mg, in proportion to dose^[3], while average weight loss rises by about one-fifth^[1]. A model pooling 48 treatment arms in type 2 diabetes likewise described “attenuation of incremental effects at higher doses”^[4]. A network meta-analysis of phase 3 trials put the average gain at about 2 to 3 points and called it modest, finding a significant advantage in percentage weight change only in its diabetes subgroup^[5]. That sits against the significant direct result in STEP UP^[1] and is a reminder that the indirect estimates carry heterogeneity^[5].

What the higher dose costs

Nausea and constipation barely separate the doses in the label’s table^[3], and STEP UP counted any gastrointestinal event in 70.8% on 7.2 mg vs 61.2% on 2.4 mg^[1]. In the label’s pooled data, 5% in each semaglutide arm stopped because of adverse reactions, against 2% on placebo^[3]. A network meta-analysis ranked 7.2 mg highest for treatment discontinuation (risk ratio 3.09 versus placebo), which is an indirect estimate and worth keeping apart from the direct comparison^[6]. Serious events in STEP UP ran 6.8% on 7.2 mg, 10.9% on 2.4 mg and 5.5% on placebo; the 2.4 mg arm had only 201 people^[1].

Dysesthesia is what really distinguishes the doses. The label groups burning sensations, skin pain, paresthesia and sensitive skin under the term^[3]. Of 288 patients who had it on 7.2 mg, 2% stopped permanently, 8% paused and 23% cut the dose. Among patients with it, 18% did not report recovering during the trial, mostly those who continued unchanged^[3]. Of 38 who recovered after action on the drug and went back to 7.2 mg, 17 (45%) had it return^[3]. So the comparison a patient faces is roughly 13 more people per 100 reaching 20% weight loss and 16 more per 100 developing dysesthesia, from different trial populations in the label’s tables^[3].

Hair loss also tracks dose, particularly in women: 8.4% of women on 7.2 mg vs 5.4% on 2.4 mg, and very few men in any arm^[3].

How well the evidence fits different people

• People who stalled on 2.4 mg. This is the group the label describes, but not the group STEP UP tested. Participants were assigned to a dose at randomization and escalated over 20 weeks, rather than moved up after falling short on 2.4 mg^[1][3]. The trial abstract does not report a response in that stalled subgroup, so the 3-point average is an extrapolation for them.
• People with type 2 diabetes. They lose less on either dose, and the absolute gap in the label is similar at -13.2% vs -10.4%^[3]. The added HbA1c benefit looks small: -1.7 vs -1.6 points from baseline, a descriptive comparison^[3]. Gastrointestinal events were close (53.1% vs 51.5%), while dysesthesia still differed (18.9% vs 4.9%)^[2].
• People already struggling on 2.4 mg. The label’s entry condition is tolerance, so ongoing side effects at the current dose fall outside its wording and are worth discussing first^[3].
• People concerned about muscle. An MRI substudy of STEP UP is too small to separate doses: 55 participants, with 43 on 7.2 mg. Pooled semaglutide showed a nonsignificant -1.1 L change in thigh muscle against placebo (P = 0.07), with sit-to-stand performance preserved^[8].
• Predicting response. A 2026 mini review names type 2 diabetes and male sex as predictors of less weight loss on semaglutide, with women losing a mean 6% more than men, and found no clear link with age or baseline BMI^[7]. Those are predictors of response to the drug in general; the abstract does not offer a way to pick out who gains specifically from the dose increase.

The alternative: changing drugs

For someone seeking more weight loss, the other realistic route is tirzepatide. In the open-label, Lilly-funded SURMOUNT-5 trial, tirzepatide at 10 or 15 mg produced -20.2% vs -13.7% with semaglutide at 1.7 or 2.4 mg over 72 weeks^[9]. No randomized trial has tested tirzepatide against semaglutide 7.2 mg in the sources reviewed here. Indirect estimates disagree in useful ways: one network meta-analysis placed tirzepatide 15 mg at -17.97% and semaglutide 7.2 mg at -14.66% against placebo^[6], while the type 2 diabetes model estimated a 94.8% probability that those two doses are equivalent within 2 points^[4]. Those are different populations and methods, and neither replaces a head-to-head trial.

Questions to raise with a prescriber

• What is the clinical reason for more weight reduction: a specific health condition or a goal we have agreed on? The label asks that it be clinically indicated^[3].
• Have I tolerated 2.4 mg for at least 4 weeks, and have I been on it long enough to judge my response^[3]?
• What should I do if tingling, burning or skin sensitivity starts? In the label’s data, dose reduction was the most common action, and events resolved faster when action was taken^[3].
• If I have diabetes and use insulin, how would my doses change? The label says adding Wegovy in patients treated with insulin has not been evaluated, and advises considering a reduction in insulin or a secretagogue when starting^[3].
• Would a different drug fit my goals better than a higher dose of this one^[9]?